BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 29936139)

  • 21. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma.
    Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S
    Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
    Ennishi D; Jiang A; Boyle M; Collinge B; Grande BM; Ben-Neriah S; Rushton C; Tang J; Thomas N; Slack GW; Farinha P; Takata K; Miyata-Takata T; Craig J; Mottok A; Meissner B; Saberi S; Bashashati A; Villa D; Savage KJ; Sehn LH; Kridel R; Mungall AJ; Marra MA; Shah SP; Steidl C; Connors JM; Gascoyne RD; Morin RD; Scott DW
    J Clin Oncol; 2019 Jan; 37(3):190-201. PubMed ID: 30523716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL.
    Shi QY; Feng X; Bao W; Ma J; Lv JH; Wang X; Rao Q; Shi QL
    J Neuropathol Exp Neurol; 2017 Nov; 76(11):942-948. PubMed ID: 29044419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EBV-positive diffuse large B-cell lymphoma features PD-L1 protein but not mRNA overexpression.
    Xue T; Wang WG; Zhou XY; Li XQ
    Pathology; 2018 Dec; 50(7):725-729. PubMed ID: 30389217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Should We Use Cell of Origin and Dual-protein Expression in Treating DLBCL?
    Riedell PA; Smith SM
    Clin Lymphoma Myeloma Leuk; 2018 Feb; 18(2):91-97. PubMed ID: 29352717
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Significance of miR-155, miR-34a and miR-30a expression in diffuse large B-cell lymphoma].
    Sun GX; Cao XS; Li Q; Wang Z; Peng J; Lu CQ
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Feb; 30(1):79-83. PubMed ID: 23450486
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-grade B-cell lymphomas with MYC and BCL2 translocations lack tumor-associated macrophages and PD-L1 expression: A possible noninflamed subgroup.
    Breinholt MF; Oliveira DVNP; Klausen TW; Gang AO; Schejbel L; Pedersen MØ; Elbaek MV; Clasen-Linde E; Nielsen SL; Knudsen H; Høgdall E; Nørgaard P
    Hematol Oncol; 2021 Aug; 39(3):284-292. PubMed ID: 33480087
    [TBL] [Abstract][Full Text] [Related]  

  • 28. UCH-L1 is induced in germinal center B cells and identifies patients with aggressive germinal center diffuse large B-cell lymphoma.
    Bedekovics T; Hussain S; Feldman AL; Galardy PJ
    Blood; 2016 Mar; 127(12):1564-74. PubMed ID: 26702068
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
    Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
    Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
    Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
    J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MYC translocation and an increased copy number predict poor prognosis in adult diffuse large B-cell lymphoma (DLBCL), especially in germinal centre-like B cell (GCB) type.
    Yoon SO; Jeon YK; Paik JH; Kim WY; Kim YA; Kim JE; Kim CW
    Histopathology; 2008 Aug; 53(2):205-17. PubMed ID: 18752503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
    Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
    Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma.
    Wang WG; Jiang XN; Sheng D; Sun CB; Lee J; Zhou XY; Li XQ
    Lab Invest; 2019 Oct; 99(10):1418-1427. PubMed ID: 31197205
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetics and diffuse large B-Cell lymphoma.
    Niroula R; Butera J
    R I Med J (2013); 2015 Nov; 98(11):23-6. PubMed ID: 26517251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
    Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
    Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Decreased CD11c-positive dendritic cells in the tumor microenvironment predict double-hit/triple-hit genotype and survival in diffuse large B-cell lymphoma.
    Yuan CT; Chuang SS; Cheng PY; Chang K; Wang H; Tsai JH; Liau JY; Chou WC
    J Pathol Clin Res; 2022 Sep; 8(5):436-447. PubMed ID: 35715938
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study.
    Thieblemont C; Briere J; Mounier N; Voelker HU; Cuccuini W; Hirchaud E; Rosenwald A; Jack A; Sundstrom C; Cogliatti S; Trougouboff P; Boudova L; Ysebaert L; Soulier J; Chevalier C; Bron D; Schmitz N; Gaulard P; Houlgatte R; Gisselbrecht C
    J Clin Oncol; 2011 Nov; 29(31):4079-87. PubMed ID: 21947824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diffuse Large B-Cell Lymphoma in Kenya: MYC, BCL2, and the Cell of Origin.
    Wawire J; Sayed S; Moloo Z; Sohani AR
    J Glob Oncol; 2019 May; 5():1-8. PubMed ID: 31045473
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nodal diffuse large B-cell lymphomas in children and adolescents: immunohistochemical expression patterns and c-MYC translocation in relation to clinical outcome.
    Gualco G; Weiss LM; Harrington WJ; Bacchi CE
    Am J Surg Pathol; 2009 Dec; 33(12):1815-22. PubMed ID: 19816150
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ASB2 is a direct target of FLI1 that sustains NF-κB pathway activation in germinal center-derived diffuse large B-cell lymphoma.
    Sartori G; Napoli S; Cascione L; Chung EYL; Priebe V; Arribas AJ; Mensah AA; Dall'Angelo M; Falzarano C; Barnabei L; Forcato M; Rinaldi A; Bicciato S; Thome M; Bertoni F
    J Exp Clin Cancer Res; 2021 Nov; 40(1):357. PubMed ID: 34763718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.